November 11, 2013

Minimum costs to produce Hepatitis C Direct Acting Antivirals

Andrew Hill and Saye Khoo, Department of Pharmacology and Therapeutics, Liverpool University, UK Bryony Simmons, Imperial College, London, UK Nathan Ford, University of Cape Town, South Africa

64th Annual Meeting of AASLD, Washington DC, United States of America, November 2013 [Poster 1097]

TREATMENT COVERAGE IS LOW EVEN IN DEVELOPED COUNTRIES

Despite the long-term morbidity & mortality associated with untreated hepatitis C, data suggests that relatively few patient are being treated.

In Europe only 3.5% of infected individuals received antiviral
treatment by the end of 2010
 
(ranging from 16% in France to <1% in Poland)
 
In the USA only 21% of infected individuals had received
treatment by the end of 2007

Reasons for under-treatment: 

      • Under-diagnosis (80% of HCV cases are asymptomatic)
      • Limitations of currently available medication
      • The very high prices of drug treatment

Click on images to enlarge them

d4a7e2bba6_Page_03

d4a7e2bba6_Page_04

d4a7e2bba6_Page_05

d4a7e2bba6_Page_06

d4a7e2bba6_Page_07

d4a7e2bba6_Page_08

d4a7e2bba6_Page_09

d4a7e2bba6_Page_10

d4a7e2bba6_Page_11

d4a7e2bba6_Page_12

d4a7e2bba6_Page_13

d4a7e2bba6_Page_14

d4a7e2bba6_Page_15

d4a7e2bba6_Page_16

d4a7e2bba6_Page_17

d4a7e2bba6_Page_18

d4a7e2bba6_Page_19

d4a7e2bba6_Page_20

d4a7e2bba6_Page_21

d4a7e2bba6_Page_22

d4a7e2bba6_Page_23

d4a7e2bba6_Page_24

d4a7e2bba6_Page_25

d4a7e2bba6_Page_26

d4a7e2bba6_Page_27

d4a7e2bba6_Page_28

d4a7e2bba6_Page_29

d4a7e2bba6_Page_30

d4a7e2bba6_Page_31

Source

Also See: Will The New Hepatitis C Drugs Trigger A Battle Over Cost?

0 comments :

Post a Comment